Linda Marie Serrano MD

Dermatology•New Berlin, WI

Resident Physician

Join to View Full Profile

12901 W National AveNew Berlin, WI 53151
Phone+1 262-787-5200
Fax+1 262-787-5299

Education & Training

Medical College of Wisconsin Affiliated HospitalsPost-Doctoral Fellowship, Dermatology, 2018
Northwestern Memorial HospitalPost-Doctoral Fellowship, 2016
Advocate Health Care/Advocate Lutheran General HospitalResidency, Internal Medicine, 2015 - 2016
University of Illinois College of MedicineClass of 2015

Certifications & Licensure

WI State Medical License 2020 - 2025
IL State Medical License 2015 - 2016
American Board of Dermatology Dermatology

Clinical Trials

Efficacy, Safety and Tolerability Study of SHAPE in IA, IB or IIA Cutaneous T-cell Lymphoma Start of enrollment: 2014 Nov 01
Unknown status
Phase 2
Clinical Study Assessing Outcomes, Adverse Events, Treatment Patterns, and Quality of Life in Patients Diagnosed With Mycosis Fungoides Cutaneous T-cell Lymphoma Start of enrollment: 2014 Nov 12
Completed
FLASH [Fluorescent Light Activated Synthetic Hypericin] Clinical Study: Topical SGX301 (Synthetic Hypericin) for the Treatment of Cutaneous T-Cell Lymphoma (Mycosis Fungoides) Start of enrollment: 2015 Dec 01
Completed
Phase 3
Safety, Tolerability and Pharmacokinetics of MRG-106 in Patients With Mycosis Fungoides (MF), CLL, DLBCL or ATLL Start of enrollment: 2016 Feb 09
Completed
Phase 1
Naloxone Hydrochloride Study for Relief of Pruritus in Patients With MF or SS Forms of CTCL Start of enrollment: 2017 Jan 01
Terminated
Phase 3
A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3) Start of enrollment: 2017 Jun 29
Completed
Phase 3
A Study of Topical Steroids as Preemptive Therapy for EGFR Inhibitor-Induced Papulopustular Eruption Start of enrollment: 2017 Feb 16
Terminated
Phase 2
A Trial to Evaluate the Efficacy and Safety of Two Concentrations of VBP-926 Solution for the Treatment of Chemotherapy-associated Paronychia in Cancer Patients Start of enrollment: 2017 Oct 24
Completed
Phase 2
Topical Sildenafil as Pre-Treatment for Hand-Foot Skin Reaction Start of enrollment: 2017 Apr 11
Completed
Early Phase 1
Join now to see all

Publications & Presentations

PubMed

9 citations
African American race is a risk factor for severe hidradenitis suppurativa.
Caden Ulschmid, Linda Serrano, Ruizhe Wu, Gretchen M Roth, Olayemi Sokumbi
International Journal of Dermatology. 2023-05-01
11 citations
Racial disparities of delay in diagnosis and dermatologic care for hidradenitis suppurativa.
Linda Serrano, Caden Ulschmid, Aniko Szabo, Gretchen Roth, Olayemi Sokumbi
Journal of the National Medical Association. 2022-12-01
4 citations
Risankizumab in moderate-to-severe plaque psoriasis.
Serrano L, Maloney, Kenneth B. Gordon
Immunotherapy. 2019-10-03

Journal Articles

Hemophagocytic Lymphohistiocytosis in Cutaneous T-cell Lymphoma
Jaehyuk Choi, Linda M Serrano, Jason B Kaplan, Barbara Pro, Joan Guitart, JAMA

Press Mentions

Not All Rashes Are Created EqualMarch 20th, 2025

Linda Marie Serrano MD

Dr. Serrano is on Doximity

Education & Training

Certifications & Licensure

Clinical Trials

Publications & Presentations

Press Mentions

Viewing the full profile is available to verified healthcare professionals only.